TWI742004B - 矽酸鋯組合物的延伸用途與其使用方法 - Google Patents
矽酸鋯組合物的延伸用途與其使用方法 Download PDFInfo
- Publication number
- TWI742004B TWI742004B TW105132645A TW105132645A TWI742004B TW I742004 B TWI742004 B TW I742004B TW 105132645 A TW105132645 A TW 105132645A TW 105132645 A TW105132645 A TW 105132645A TW I742004 B TWI742004 B TW I742004B
- Authority
- TW
- Taiwan
- Prior art keywords
- less
- composition
- zirconium silicate
- ion
- item
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title abstract description 14
- 229910001414 potassium ion Inorganic materials 0.000 claims description 28
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 19
- 208000002682 Hyperkalemia Diseases 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 15
- 239000011734 sodium Substances 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 4
- 238000005341 cation exchange Methods 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 claims description 3
- NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical compound [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 claims description 3
- BUAKPNXRPHOMCG-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4][Ce+4] BUAKPNXRPHOMCG-UHFFFAOYSA-N 0.000 claims description 3
- CULSIAXQVSZNSV-UHFFFAOYSA-N germanium(4+) Chemical compound [Ge+4] CULSIAXQVSZNSV-UHFFFAOYSA-N 0.000 claims description 3
- GVOLZAKHRKGRRM-UHFFFAOYSA-N hafnium(4+) Chemical compound [Hf+4] GVOLZAKHRKGRRM-UHFFFAOYSA-N 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- QUWPZPLTANKXAM-UHFFFAOYSA-N niobium(5+) Chemical compound [Nb+5] QUWPZPLTANKXAM-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 claims description 3
- 229910001419 rubidium ion Inorganic materials 0.000 claims description 3
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- DUFCMRCMPHIFTR-UHFFFAOYSA-N 5-(dimethylsulfamoyl)-2-methylfuran-3-carboxylic acid Chemical compound CN(C)S(=O)(=O)C1=CC(C(O)=O)=C(C)O1 DUFCMRCMPHIFTR-UHFFFAOYSA-N 0.000 description 12
- 239000008119 colloidal silica Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 9
- 239000004115 Sodium Silicate Substances 0.000 description 8
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 8
- 229910052911 sodium silicate Inorganic materials 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- 230000006793 arrhythmia Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022822 Intravascular haemolysis Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229910006249 ZrSi Inorganic materials 0.000 description 1
- GNKTZDSRQHMHLZ-UHFFFAOYSA-N [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] Chemical compound [Si].[Si].[Si].[Ti].[Ti].[Ti].[Ti].[Ti] GNKTZDSRQHMHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- -1 ammonium ions Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229940059939 kayexalate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/02—Processes using inorganic exchangers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/14—Base exchange silicates, e.g. zeolites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
- C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
- C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
- C01B39/06—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis
- C01B39/08—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis the aluminium atoms being wholly replaced
- C01B39/085—Group IVB- metallosilicates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Geology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/883,428 US9592253B1 (en) | 2015-10-14 | 2015-10-14 | Extended use zirconium silicate compositions and methods of use thereof |
| US14/883,428 | 2015-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201717972A TW201717972A (zh) | 2017-06-01 |
| TWI742004B true TWI742004B (zh) | 2021-10-11 |
Family
ID=58227650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105132645A TWI742004B (zh) | 2015-10-14 | 2016-10-07 | 矽酸鋯組合物的延伸用途與其使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9592253B1 (enExample) |
| EP (1) | EP3362456A4 (enExample) |
| JP (1) | JP6546700B2 (enExample) |
| KR (1) | KR102667566B1 (enExample) |
| CN (2) | CN108137620B (enExample) |
| AR (1) | AR106369A1 (enExample) |
| AU (1) | AU2016338753C1 (enExample) |
| CA (1) | CA3000950C (enExample) |
| CL (1) | CL2018000916A1 (enExample) |
| CR (1) | CR20180276A (enExample) |
| EA (2) | EA035890B1 (enExample) |
| HK (1) | HK1254808A1 (enExample) |
| IL (1) | IL258478B (enExample) |
| MX (1) | MX2018004440A (enExample) |
| MY (1) | MY187088A (enExample) |
| PH (1) | PH12018500786B1 (enExample) |
| TW (1) | TWI742004B (enExample) |
| WO (1) | WO2017066128A1 (enExample) |
| ZA (1) | ZA201803095B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900037T1 (it) | 2011-02-11 | 2019-02-28 | Zs Pharma Inc | Uso di un silicato di zirconio per il trattamento di iperkaliemia |
| US9592253B1 (en) * | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
| WO2019092179A1 (en) * | 2017-11-10 | 2019-05-16 | Sandoz Ag | Pharmaceutical compositions comprising zs-9 |
| CN113557024A (zh) | 2019-03-13 | 2021-10-26 | 阿斯利康(瑞典)有限公司 | 用于血液透析患者中使用的钾结合剂 |
| CN117342570A (zh) * | 2023-09-04 | 2024-01-05 | 杭州国瑞生物科技有限公司 | 一种环硅酸锆钠的a晶型及其制备方法 |
| WO2024061387A2 (zh) * | 2023-12-19 | 2024-03-28 | 杭州国瑞生物科技有限公司 | 一种环硅酸锆钠的b晶型及其制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579460B1 (en) * | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
| US7201885B1 (en) * | 2005-11-17 | 2007-04-10 | J.M. Huber Corporation | Method of removing heavy metals from silicate sources during silicate manufacturing |
| EP1787960A1 (en) * | 2005-11-17 | 2007-05-23 | J.M. Huber Corporation | Method of removing heavy metals from silicate sources during silicate manufacturing |
| US20120213847A1 (en) * | 2011-02-11 | 2012-08-23 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE21224E (en) | 1939-10-03 | Coherent zirconium silicates | ||
| US2809943A (en) * | 1952-09-11 | 1957-10-15 | Dow Chemical Co | Weighted ion exchange resin granules and method of making same |
| US3492092A (en) * | 1966-04-04 | 1970-01-27 | Chem Separations Corp | Ion exchange process for treating crude mineral solutions |
| US3947279A (en) | 1971-12-23 | 1976-03-30 | Owens-Illinois, Inc. | Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same |
| US4581141A (en) | 1978-02-27 | 1986-04-08 | Purdue Research Foundation | Dialysis material and method for removing uremic substances |
| FR2444005A1 (fr) | 1978-12-15 | 1980-07-11 | Ugine Kuhlmann | Procede industriel de fabrication en semi-continu de zeolithe a |
| US4943545A (en) | 1987-06-08 | 1990-07-24 | Mobil Oil Corporation | Activation of zeolites |
| US5015453A (en) | 1989-04-28 | 1991-05-14 | W. R. Grace & Co.-Conn. | Crystalline group IVA metal-containing molecular sieve compositions |
| US5338527A (en) | 1992-08-20 | 1994-08-16 | Uop | Zirconium silicate composition, method of preparation and uses thereof |
| ATE142170T1 (de) | 1992-10-28 | 1996-09-15 | Crosfield Joseph & Sons | Kieselsäuren |
| US5518707A (en) | 1994-10-24 | 1996-05-21 | Uop | Metallo germanates |
| IT1283284B1 (it) | 1996-03-21 | 1998-04-16 | Eniricerche Spa | Zeolite ers-10 e procedimento per la sua preparazione |
| FR2750893B1 (fr) | 1996-07-12 | 1998-10-30 | Elf Aquitaine | Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application |
| US5888472A (en) | 1997-04-08 | 1999-03-30 | Uop Llc | Zirconium silicate molecular sieves and process using the same |
| US5891417A (en) | 1997-04-08 | 1999-04-06 | Uop Llc | Zirconium silicate and zirconium germanate molecular sieves and process using the same |
| CA2268888A1 (en) | 1997-05-12 | 1998-11-19 | Itsuki Uehara | Separator for battery and alkali secondary battery using the same |
| US6007790A (en) | 1998-08-13 | 1999-12-28 | Uop Llc | Family of microporous indium silicate compositions |
| US6332985B1 (en) | 1999-03-29 | 2001-12-25 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| US6099737A (en) | 1999-03-29 | 2000-08-08 | Uop Llc | Process for removing toxins from blood using zirconium metallate or titanium metallate compositions |
| US7041274B2 (en) | 1999-10-22 | 2006-05-09 | Intevep, S.A. | Aluminosilicate compositions, preparation and use |
| US20020061521A1 (en) | 2000-01-31 | 2002-05-23 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US6379641B1 (en) | 2000-05-01 | 2002-04-30 | Uop Llc | Microporous rare earth silicates and method of producing same |
| US6596254B1 (en) | 2000-06-12 | 2003-07-22 | Sandia Corporation | Niobate-based octahedral molecular sieves |
| AU2002242103A1 (en) | 2001-02-06 | 2002-08-19 | Ash Medical Systems, Inc. | Monovalent-selective cation exchangers as oral sorbent therapy |
| US6814871B1 (en) | 2001-07-13 | 2004-11-09 | Uop Llc | Process for removing pollutants from aqueous streams |
| US6689335B1 (en) | 2002-12-19 | 2004-02-10 | Eastman Kodak Company | Silver ion sequester and release agent |
| JP4671419B2 (ja) | 2003-12-15 | 2011-04-20 | 旭化成ケミカルズ株式会社 | 多孔性成形体及びその製造方法 |
| GB2430368B (en) | 2004-03-30 | 2009-08-26 | Ilypsa Inc | Methods and compositions for treatment of ion imbalances |
| US8192758B2 (en) * | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| JP5328152B2 (ja) | 2004-12-28 | 2013-10-30 | レナル ソリューションズ，インク． | リン酸ジルコニウム粒子の合成法 |
| US7967984B2 (en) | 2005-06-14 | 2011-06-28 | Asahi Kasei Chemicals Corporation | Apparatus for water treatment and method of treating water |
| CN101316601A (zh) | 2005-09-30 | 2008-12-03 | 伊立普萨公司 | 从哺乳动物的胃肠道选择性除去钾离子的方法和组合物 |
| CN101321519A (zh) | 2005-09-30 | 2008-12-10 | 伊立普萨公司 | 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物 |
| US8367112B2 (en) | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
| WO2007127390A2 (en) | 2006-04-28 | 2007-11-08 | Biolife, L.L.C. | Materials and methods for wound treatment |
| WO2008082087A1 (en) | 2007-01-03 | 2008-07-10 | Insilicotech Co., Ltd | Coordination polymer crystal with porous metal-organic frameworks and preperation method thereof |
| ES2304890B1 (es) | 2007-04-03 | 2009-10-30 | Universidad De Zaragoza | Procedimiento de obtencion de esferas de titanosilicato. |
| JP5583606B2 (ja) | 2008-02-26 | 2014-09-03 | コーニング インコーポレイテッド | ケイ酸塩ガラス用の清澄剤 |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| CN103919792B (zh) | 2008-08-22 | 2018-03-09 | 瑞立普萨公司 | 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用 |
| US8865121B2 (en) | 2009-06-18 | 2014-10-21 | Basf Se | Organotemplate-free synthetic process for the production of a zeolitic material |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| US20120070468A1 (en) | 2010-09-16 | 2012-03-22 | Uop Llc | Removal of toxins from gastrointestinal fluids |
| EP2694437B1 (en) | 2011-04-08 | 2020-10-21 | Basf Se | Process for producing acylation catalyst |
| US9527751B2 (en) | 2011-11-11 | 2016-12-27 | Basf Se | Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure |
| EP2812281B1 (en) | 2012-02-06 | 2020-07-29 | Basf Se | Iron- and copper-containing zeolite beta from organotemplate-free synthesis and use thereof in the selective catalytic reduction of nox |
| US9475041B2 (en) | 2012-04-24 | 2016-10-25 | Basf Se | Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds |
| MX2015000381A (es) * | 2012-07-11 | 2015-11-23 | Zs Pharma Inc | Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia. |
| KR102184602B1 (ko) * | 2012-10-22 | 2020-11-30 | 제트에스 파마, 인코포레이티드 | 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트 |
| CA2908641C (en) * | 2013-04-05 | 2022-10-18 | ZS Pharma, Inc. | Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease |
| KR102332954B1 (ko) * | 2013-11-08 | 2021-11-29 | 제트에스 파마, 인코포레이티드 | 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄 |
| EP3079706A4 (en) * | 2013-12-10 | 2017-12-27 | ZS Pharma, Inc | Zirconium silicate for treating hyperkalemia without co-administering lithium |
| US9592253B1 (en) * | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
-
2015
- 2015-10-14 US US14/883,428 patent/US9592253B1/en active Active
-
2016
- 2016-10-07 TW TW105132645A patent/TWI742004B/zh active
- 2016-10-10 PH PH1/2018/500786A patent/PH12018500786B1/en unknown
- 2016-10-10 EP EP16856007.6A patent/EP3362456A4/en active Pending
- 2016-10-10 MX MX2018004440A patent/MX2018004440A/es active IP Right Grant
- 2016-10-10 MY MYPI2018701456A patent/MY187088A/en unknown
- 2016-10-10 EA EA201890875A patent/EA035890B1/ru not_active IP Right Cessation
- 2016-10-10 CN CN201680059460.9A patent/CN108137620B/zh active Active
- 2016-10-10 CN CN202110531403.9A patent/CN113143958A/zh active Pending
- 2016-10-10 JP JP2018519853A patent/JP6546700B2/ja active Active
- 2016-10-10 AU AU2016338753A patent/AU2016338753C1/en active Active
- 2016-10-10 WO PCT/US2016/056286 patent/WO2017066128A1/en not_active Ceased
- 2016-10-10 EA EA202091273A patent/EA202091273A1/ru unknown
- 2016-10-10 CA CA3000950A patent/CA3000950C/en active Active
- 2016-10-10 KR KR1020187013243A patent/KR102667566B1/ko active Active
- 2016-10-10 CR CR20180276A patent/CR20180276A/es unknown
- 2016-10-10 HK HK18113894.0A patent/HK1254808A1/zh unknown
- 2016-10-14 AR ARP160103150A patent/AR106369A1/es active IP Right Grant
-
2017
- 2017-01-31 US US15/421,132 patent/US10300087B2/en active Active
-
2018
- 2018-04-01 IL IL258478A patent/IL258478B/en active IP Right Grant
- 2018-04-10 CL CL2018000916A patent/CL2018000916A1/es unknown
- 2018-05-11 ZA ZA201803095A patent/ZA201803095B/en unknown
-
2019
- 2019-05-17 US US16/415,550 patent/US11738044B2/en active Active
-
2023
- 2023-07-07 US US18/348,799 patent/US20240009229A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579460B1 (en) * | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
| US7201885B1 (en) * | 2005-11-17 | 2007-04-10 | J.M. Huber Corporation | Method of removing heavy metals from silicate sources during silicate manufacturing |
| EP1787960A1 (en) * | 2005-11-17 | 2007-05-23 | J.M. Huber Corporation | Method of removing heavy metals from silicate sources during silicate manufacturing |
| US20120213847A1 (en) * | 2011-02-11 | 2012-08-23 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI742004B (zh) | 矽酸鋯組合物的延伸用途與其使用方法 | |
| JP6251354B2 (ja) | 高カリウム血症の処置のための微孔質ジルコニウムケイ酸塩 | |
| CN104797263B (zh) | 用于治疗高钾血症的微孔硅酸锆 | |
| JP6333926B2 (ja) | 混合金属化合物 | |
| KR20150140750A (ko) | 칼륨의 감소 및 만성 신장 및/또는 만성 심장 질환의 치료를 위한 미세다공성 규산지르코늄 및 이뇨제 | |
| HK40056754A (en) | Extended use zirconium silicate compositions and methods of use thereof | |
| EA041680B1 (ru) | Композиции на основе силиката циркония для длительного применения и способы их применения | |
| BR112018007189B1 (pt) | Composições de troca catiônica, medicamento para tratamento de hipercalemia, e uso das composições | |
| CN101948469B (zh) | 柠檬酸小檗碱合成方法 | |
| CN106232126A (zh) | 用于治疗高钾血症、不共同施用锂的硅酸锆 | |
| HK1211494B (en) | Microporous zirconium silicate for treating hyperkalemia |